In various xenograft models using human-derived tumors or tumor cell lines expressing EML4- or NPM–ALK fusion proteins, Crizotinib inhibited tumor growth, decreased proliferation, increased apoptosis, and dose-dependently decreased phosphorylation. This evidence concerns the gene EML4 and neoplasm.